IP Library Granted Patent US 7,888,019
Granted Patent B2
US 7,888,019 · App. 11/731,196 · Granted Feb 15, 2011

Genes involved estrogen metabolism

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,888,019
App. No.
11/731,196
Granted
Feb 15, 2011
Kind
B2
Abstract

The invention concerns genes that have been identified as being involved in estrogen metabolism, and are useful as diagnostic, prognostic and/or predictive markers in cancer. In particular, the invention concerns genes the tumor expression levels of which are useful in the diagnosis of cancers associated with estrogen metabolism, and/or in the prognosis of clinical outcome and/or prediction of drug response of such cancers.

Claims (13)

1. A method of predicting the likelihood of a positive clinical outcome for a human subject diagnosed with breast cancer, comprising:

assaying an expression level of (a) an RNA transcript of GSTM2, and (b) an RNA transcript of GSTM3 in a tumor sample obtained from said subject;

normalizing the RNA levels of GSTM2 and GSTM3 against the RNA level of one or more reference genes to obtain normalized expression levels of GSTM2 and GSTM3;

using the normalized expression levels of GSTM2 and GSTM3 to generate information comprising a prediction of the clinical outcome for said subject,

wherein the normalized expression levels of GSTM2 and GSTM3 are positively correlated with a positive clinical outcome; and

generating a report based on the information.

2. The method of claim 1 wherein said expression levels are obtained by a method of gene expression profiling.

3. The method of claim 2 wherein said method is a PCR-based method.

4. The method of claim 1 wherein the tumor sample is obtained by biopsy.

5. The method of claim 1 , wherein the tumor sample comprises fragmented RNA.

6. The method of claim 1 , wherein the report further comprises information concerning a risk of cancer recurrence for said subject.

7. The method of claim 1 , wherein the report further comprises information to guide a cancer treatment decision for said subject.

8. The method of claim 1 , further comprising assaying an expression level of at least one additional RNA transcript selected from the group GSTM4, GSTM5, NAT1, TFRC, MVP, PRAME, PPIH, and CYP4Z1.

Assignments (3)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENT RIGHTS (REEL/FRAME 69898/0380) Recorded Mar 27, 2026
From: JPMORGAN CHASE BANK, N.A.
To: GENOMIC HEALTH, INC.
Reel/Frame 075294/0821 →
PATENT SECURITY AGREEMENT Recorded Jan 14, 2025
From: GENOMIC HEALTH, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 069898/0380 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2007
From: KIEFER, MICHAEL C.; BAKER, JOFFRE B.; HACKETT, JAMES
To: GENOMIC HEALTH, INC.
Reel/Frame 019683/0772 →